Chad Bjorklund

Chad Bjorklund currently serves as the Director Multiple Myeloma Disease Lead at Bristol Myers Squibb since November 2019, after holding the roles of Scientific Associate Director and Principal Scientist within the same company. Prior to this, Chad Bjorklund worked as a Senior Scientist at Celgene from January 2013 to November 2019. Earlier in the career, Chad Bjorklund was a Postdoctoral Research Fellow at MD Anderson Cancer Center from September 2007 to January 2013. Chad Bjorklund earned a Doctor of Philosophy (Ph.D.) in Biochemistry and Biophysics from Washington State University in 2006 and a Bachelor's Degree in Biochemistry from Boise State University in 2002.